Full-Time

Embedded System Engineer 1

Medical Devices

Posted on 6/10/2025

Cardiosense

Cardiosense

11-50 employees

Non-invasive cardiac monitoring with AI analytics

Compensation Overview

$70k - $90k/yr

Chicago, IL, USA

In Person

Category
Hardware Engineering (1)
Required Skills
Altium
OrCAD
Requirements
  • Bachelors in Electrical Engineering, Biomedical Engineer, Mechanical Engineering, or related fields. Master’s preferred.
  • 2+ years of hands-on experience in hardware design and development, preferably in the medical device industry.
  • Proficiency in circuit design, schematic capture, and PCB layout tools (e.g., Altium, OrCAD, Eagle).
  • Experience with biomedical non-invasive sensor technologies such as electrocardiogram and photoplethysmogram.
  • Experience with embedded systems, microcontrollers designs, and Embedded C/Python.
  • Strong analytical thinking and problem-solving abilities.
  • Proven ability to influence cross-functional teams and stakeholders.
Responsibilities
  • Design, develop, and test electronic systems for medical devices, ensuring compliance with regulatory requirements.
  • Work on circuit design, PCB layout, and system integration of embedded electronics. Contribute to mechanical design as needed.
  • Design and conduct feasibility studies, risk assessments, and validation testing for new designs.
  • Contribute to manufacturing processes and develop end-of-line testing routines to ensure high-quality devices.
  • Document requirements, design specifications, test results, and regulatory compliance reports.
  • Stay updated with industry trends, emerging technologies, and regulatory changes in medical devices.

Cardiosense develops a non-invasive cardiac monitoring platform that uses wearable biometric sensors and artificial intelligence to analyze the full electromechanical behavior of each heartbeat. The system continuously tracks heart electrical signals and mechanical activity to provide early warnings of declining heart function. By selling the devices and offering a subscription-based analytics platform, Cardiosense targets hospitals and clinics to help healthcare teams prioritize at-risk patients and enable proactive interventions. Unlike traditional monitoring that relies on invasive methods or single-signal data, Cardiosense combines multiple data streams and AI-driven insights to detect signs of deterioration before symptoms appear. The company aims to improve patient outcomes by enabling timely care while the technology remains investigational under U.S. law.

Company Size

11-50

Company Stage

Series A

Total Funding

$15.1M

Headquarters

Chicago, Illinois

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • CMS expanded remote patient monitoring reimbursement codes in 2025 directly fund heart failure management platforms.
  • Heart failure readmission costs exceed $40 billion annually, creating strong payer incentives for early detection.
  • EHR integration becoming standard requirement positions Cardiosense for rapid Epic and Cerner health system deployment.

What critics are saying

  • CardiosensAI competitor predicts cardiac events 24 hours in advance with real-time AI, eroding first-mover advantage.
  • FDA approval delays beyond investigational use block CardioTag commercialization and analytics subscription revenue streams.
  • Burn rate exhaustion post-$15.1M Series A with no Series B evident forces dilution or shutdown.

What makes Cardiosense unique

  • Multi-modal sensor fusion (ECG, SCG, PPG) achieves 92% accuracy correlating with invasive hemodynamic measurements.
  • FDA Breakthrough Device designation for early heart failure detection algorithm enables expedited regulatory pathway.
  • Physiological waveform AI platform generates actionable decompensation risk biomarkers, not passive data collection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

2%
VC News Daily
Dec 8th, 2022
Cardiosense Receives $15.1M Series A Round

Cardiosense Receives $15.1M Series A Round Back to HomeCHICAGO, IL, Cardiosense announced that it has raised $15.1 million in Series A funding.Cardiosense, a digital health company leveraging artificial intelligence and multi-sensor devices to enable early detection of cardiovascular disease, announced today that it has raised $15.1 million in Series A funding, co-led by Broadview Ventures and Hatteras Venture Partners, with participation from Laerdal Million Lives Fund, OSF Ventures, UnityPoint Health Ventures, and Portal Innovations. The capital will be used to support team expansion, accelerate product development, and fund an expansive heart failure study.Cardiosense is building a physiological waveform AI platform to develop predictive biomarkers to detect and manage cardiac disease. The Company has developed a suite of novel digital tools, multi-sensor devices, and analysis algorithms to detect early signs of cardiovascular disease, inform personalized therapy, and improve patient outcomes.(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page

INACTIVE